SUMMARY Ten patients with severe primary pulmonary hypertension and pronounced disability who were unresponsive to oral vasodilators were treated with intravenous epoprostenol (prostacyclin). All had been referred for heart and lung transplantation. Short term administration of epoprostenol (mean dose 5-5 ng/kg/min) increased the mean cardiac index from 1-8 to 2 2 1/min/m2, improved pulmonary artery oxygen saturation from 48% to 57%, and increased calculated tissue oxygen delivery from 10 to 11 -8 ml/kg/min. The mean pulmonary vascular resistance fell by 18% while mean systemic artery pressure fell by 32%. Pulmonary artery pressure rose in only two patients. Continued intravenous infusion of epoprostenol for 1-25 months was associated with subjective and clinical improvement. Exercise tolerance improved as measured by an increase in the maximum rate of oxygen consumption during progressive exercise testing. In those six patients who were able to exercise before treatment it rose from a mean of 7 to 15 ml/kg/min. Those who had been unable to exercise before treatment achieved comparable rates of oxygen consumption after treatment. Two patients died on treatment, three have undergone heart-lung transplantation, and in five the treatment is continuing. Complications included episodes of septicaemia and ascites.
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In this uncontrolled study of patients with severe pulmonary hypertension epoprostenol seemed to offer a means of optimally dosing the patients with a vasodilator to reduce pulmonary vascular resistance and thus increasing cardiac output and oxygen tissue delivery. There was no evidence to suggest that this treatment influenced the progress of the disease.
Primary pulmonary hypertension is defined as pulmonary arterial hypertension of unknown cause,l and has been shown to be associated with three distinct pulmonary diseases2: pulmonary venoocclusive disease, which can have characteristic clinical features,3 so called recurrent thromboembolism; and plexogenic arteriopathy. Most clinicians regard plexogenic pulmonary arteriopathy as true primary pulmonary hypertension but it can be difficult to distinguish this disease from thrombotic pulmonary hypertension on the basis of clinical or haemodynamic variables. 4 Primary pulmonary hypertension has a poor prognosis and no treatment has been shown to reverse its progress.5
Oral vasodilator treatment can reduce the increased pulmonary vascular resistance and increase the low cardiac output characteristic of the disease,6 7 and sustained clinical improvement has been reported in a small proportion of patients. Such treatment can also produce severe and refractory systemic hypotension.89
An intravenous infusion of epoprostenol (prostacyclin) induced short term pulmonary vasodilatation in primary pulmonary hypertension.'o Because of its short half life, the dose can be titrated to produce a desired haemodynamic effect and any adverse effects are reversed immediately by discontinuing the infusion. It is a safe agent to use for the initial testing of a patient's responsiveness to a vasodilator'0 but it has not been used on a long term basis because no oral preparation is available. We have previously shown that long term treatment of Treatment of primary pulmonary hypertension with intravenous epoprostenol (prostacyclin) Pao2 (5) saturation('.) 62 (2) 49 (3) <0-001 2 The maximum walking speed (WS) attained in km/h and the maximum oxygen consumption attained in ml/kg/min (V Max 02) were recorded.
In an attempt to obtain maximum clinical benefit seven of the patients had one or more dosage increments during their long term treatment. Each increase was achieved during a period of hospital admission in which the systemic blood pressure was closely monitored.
The paired t test was used for statistical analysis of recorded data before and after intervention.
Results

SHORT TERM EFFECTS OF EPOPROSTENOL
The baseline measurements confirmed the presence of severe pulmonary hypertension in the 10 patients. Mean pulmonary artery pressure and pulmonary small increase in mean heart rate during the infusion but no change in pulmonary arterial wedge or right atrial pressures. The mean falls in pulmonary vascular and systemic vascular resistances were 19% and 32% respectively. In only two patients (1 and 5) was the fall in pulmonary vascular resistance greater than the fall in systemic vascular resistance.
EFFECTS OF LONG TERM EPOPROSTENOL
All but patient 9 noted a subjective improvement in well-being and exercise tolerance within a week of starting long term treatment. The subjective benefit was confirmed on formal exercise testing (fig 1) . Four patients were too ill to exercise before epoprostenol but after long term treatment they reached a mean walking speed (SEM) of 4 (0 6) km/h and a mean maximum oxygen consumption of 13-4 (2 0) ml/kg/min. The six patients who exercised shortly before starting epoprostenol increased their mean walking speed from 2-5 (0-7) to 4-3 (0-6) km/h (p < 0-01) and their maximum oxygen consumption from 7 2 (0 7) to 14 9 (1 4) ml/kg/min (p < 0-01). All patients showed an initial improvement in exercise performance during epoprostenol treatment. Figure  1 shows that individual exercise performances continued to improve or were sustained in some patients while in others improvement was only temporary.
Subjective benefit was held to be present if the patients reported improved symptoms and exercise tolerance that worsened within 30 minutes of the infusion being interrupted. Figure 2 shows that five patients have felt better on epoprostenol for over 24 weeks to 2 years.
CLINICAL PROGRESS
All patients (except patient 6) initially were able to leave hospital and return home to an improved quality of life. Three of the patients have since undergone heart-lung transplantation. Patients 1 and 3 remained well on the infusion until short periods of deterioration prompted operation. Patient 5 did well initially but then suffered two episodes of septicaemia, the second of which was associated with a cardiorespiratory arrest. She slowly recovered and subsequently had a heart-lung transplant.
After initial improvement patient 6 had a relapse into refractory right ventricular failure after a cardiorespiratory arrest during follow up cardiac catheterisation. This event was not associated with any change in epoprostenol dosage and appeared to occur during repositioning of the catheter. Recurrent massive ascites and renal failure developed and the patient died five months after starting treatment. After an impressive initial response, patient 2 slipped back to her previous condition. The infusion was stopped for a short time and reintroduction of epoprostenol at a higher dose was associated with a further impressive response. After 10 months' treatment, however, she relapsed into gross right ventricular failure which was unresponsive to an increasing dose of epoprostenol.
The other five patients have received epoprostenol for a comparatively short time but all report sustained benefit.
SIDE EFFECTS OF LONG TERM TREATMENT
In three patients septicaemia developed from infection at the tip of the indwelling cannula. In each case this was associated with a deterioration in well-being and exercise ability. In patients 1 and 3 it responded 0 0 275 group.bmj.com on June 22, 2017 -Published by http://heart.bmj.com/ Downloaded from quickly to intravenous antibiotics and replacement of the intravenous cannula. In patient 5 two courses of antibiotics and resiting of the subclavian cannula did not eradicate the infection. Epoprostenol had to be given through a peripheral vein until the infection was controlled; then a further subclavian line was inserted.
Sterile ascites developed in three patients during long term treatment. In each case the fluid was straw coloured and contained a predominance of lymphocytes. The glucose and amylase concentrations of the fluid were normal but in each case the total protein content was > 35 g/l and electrophoresis showed a protein leak which was non-selective according to the results of molecular weight determinations. No patient had a raised erythrocyte sedimentation rate at diagnosis and in two of the patients tested antinuclear factor, DNA binding, and rheumatoid factor were not detected in the peripheral blood. Liver function tests showed a slight increase in aspartate aminotransferase concentrations. Patient 1 had normal computed tomographs of the liver and abdomen.
In patient 1 the ascites did not recur after paracentesis. In patient 2 it became massive and required repeated aspiration. In patient 6 it was massive, recurrent, and became chylous shortly before death. In all three patients the ascites was greater than would be expected from right ventricular failure alone and was not associated with generalised fluid retention of the same magnitude.
Higher doses of epoprostenol were tolerated by the patients than by normal volunteers. This was achieved without the commonly reported side effects of headache, flushing, and abdominal pain. 13 When these side effects did occur they were associated with an increase in the infusion dose but they were transient in nature, and normally subsided within 24 hours. We learnt to control side effects by increasing the infusion rate more gradually. In general the patients managed their treatment with very few problems. Five patients experienced sudden interruptions in their infusions; one because of pump failure, one because the line became disconnected, and three because they inadvertently turned off the pump. All noticed a considerable increase in symptoms within minutes and a prompt improvement when the infusion was restarted.
PATHOLOGICAL EXAMINATION
Histological specimens obtained in six patients showed medial hypertrophy of the pulmonary arterioles with widespread fibrocellular proliferation of the intima of all arteries and arterioles. In patients 1, 4, and 5 the changes were typical of plexiform pulmonary arteriopathy but in patients 2, 3, and 10 the Jones, Higenbottam, Wallwork vascular changes were associated with the presence of thrombi in peripheral pulmonary arteries. Patient 5 had an open lung biopsy before epoprostenol and both lungs were available for examination after heart-lung transplantation. There was no difference in the severity of the vascular lesions between the two specimens. Discussion This paper is not the report of a clinical trial but rather the observations of the effect of a treatment on ten patients with a severe, potentially fatal condition. Nevertheless, we made several important observations based on the subjective and objective data. These patients were treated with epoprostenol because all had severe primary pulmonary hypertension with a high pulmonary artery pressure and pulmonary vascular resistance and low cardiac index. All had a pulmonary arterial oxygen saturation below 63%, which is associated with a three year survival rate of < 200%.4 In all, the symptoms were becoming worse and this was confirmed by haemodynamic measurements, a fall in pulmonary arterial oxygen saturation between catheterisations, and in four a measured decline in exercise capacity and maximum oxygen consumption. None had responded to conventional oral vasodilators.
The rationale behind the use of vasodilators in primary pulmonary hypertension is that the histological features of the condition may represent an inappropriate constriction of the pulmonary vasculature. 4 In the early stages of the disease the vasoconstriction is labile and responsive to vasodilators but later it becomes fixed and irreversible.15 Short term administration of vasodilators in primary pulmonary hypertension most commonly causes a decrease in the pulmonary and systemic vascular resistance and an associated increase in cardiac output with little or no effect on the pulmonary artery pressure. 16 Treatment of primary pulmonary hypertension with intravenous epoprostenol (prostacyclin) infusion, fluctuations in the blood concentration due to variable bioavailability are avoided, thus making it ideally suited to treatment of critically ill patients. It is possible that the problem with oral vasodilators is the maintenance of adequate concentrations in the blood.
The effect of short term infusion of epoprostenol in our patients was similar to that reported previously.10 Some workers have claimed that in order to establish a pulmonary vasodilatation effect, there should be a fall in pulmonary artery pressure and the pulmonary vascular resistance should decrease more than systemic vascular resistance."6 Only two of our patients fulfilled these criteria. The cardiac output, however, improved with no rise in pulmonary artery pressure in all but two patients. This improved cardiac output was associated with concomitant increases in pulmonary arterial oxygen saturation and peripheral oxygen delivery. The increase in cardiac output was achieved without a large increase in heart rate or a change in right atrial pressure, suggesting there was no important increase in right ventricular workload.
In assessing the effect of long term epoprostenol, the ideal would be to repeat haemodynamic measurements. Right heart catheterisation is not without complications,'8 however, and in primary pulmonary hypertension is associated with a significant morbidity and mortality4 as we witnessed in patient 6 . Also although our patients' recordings were stable during their catheterisations, there can be spontaneous variability of haemodynamic function in primary pulmonary hypertension. '9 Because the increase in cardiac output was the major effect of epoprostenol we monitored our patients' progress non-invasively by means of treadmill exercise testing. Measurement of symptom limited maximum oxygen consumption has been shown to correlate with the cardiac output in normal subjects20 and patients with left heart failure.2' A recent paper has recommended its use also in assessing the response to oral vasodilators in "obliterative pulmonary hypertension".22 All our patients improved clinically and subjectively and all increased their maximum oxygen consumption during exercise. This indicated that their improvement in cardiac output during the short term was sustained by the long term infusion. We believe that the symptomatic benefit of long term epoprostenol was due to its ability to increase cardiac output and tissue oxygenation; this resembles the mechanism of action of a response to oral hydralazine in patients with primary pulmonary hypertension.23 24 Exactly how the increase in cardiac output is achieved remains uncertain but even in the absence of a fall in pulmonary artery pressure it probably represents some decrease in the obstruction of the pulmonary vasculature.25 The mechanism is analogous to that which operates when vasodilators are given to patients with left ventricular dysfunction when reduction in afterload is accompanied by an increase in cardiac output rather than a fall in systemic arterial pressure. In both instances a fall in systemic arterial pressure resulting from a fall in systemic vascular resistance is counteracted by reflex increase in stroke volume.
The reason why all our patients responded both in the short term and in the long term is probably because we were able to reach the optimum vasodilating dose with the epoprostenol infusion; this is much more difficult to achieve with oral vasodilators.
Even when a clinical diagnosis of primary pulmonary hypertension has been made after extensive investigations including pulmonary angiography, other studies of necropsy specimens have shown that up to 600o of patients have evidence of recurrent pulmonary thromboembolism.4 14 This was also seen in three of our six patients in whom the results of histological examination were available (patients 2, 3, and 10). In all of them pulmonary angiograms had excluded major vessel obstruction. Their short term and long term responses were similar to those in patients with classic plexiform pulmonary arteriopathy. It could be argued that the thrombi occurred in situ; however, in our group of patients the sex ratio is not typical of the usually recognised condition.
Some evidence suggests that anticoagulation may prolong survival4 but most physicians believe that anticoagulants are useful only in preventing the secondary thromboembolism associated with low cardiac output.26 As well as being a vasodilator, epoprostenol is a powerful platelet antiaggregator and if abnormal platelet behaviour was important in the pathogenesis of primary pulmonary hypertension this effect might be an added benefit of the treatment. Tests of platelet function in patients on epoprostenol infusions, however, showed an "intrainfusion" rebound of platelet activation starting at 2-4 days, reaching a maximum at [6] [7] [8] [9] [10] Jones, Higenbottam, Wallwork underlying disease process as its effects were not sustained in all patients. The two patients who died had the lowest pulmonary arterial oxygen saturation at the outset. It had no effect on the pulmonary pathology of the one patient whose lungs were examined before and after epoprostenol and in whom stopping the infusion had caused a rapid deterioration in clinical condition.
Treatment with epoprostenol improved the quality of life and the exercise tolerance in patients with a severe deteriorating disease who had not been helped by oral vasodilators. We believe that despite the problems of maintaining an intravenous infusion and the expense, this is a treatment that can be used in patients awaiting heart-lung transplantation when there may be a long wait for a suitable donor. A formal controlled study will be necessary, however, if epoprostenol infusion is to be considered for more general use in less severely affected patients with primary pulmonary hypertension. 
